相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Nadia Harbeck et al.
CANCERS (2021)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley et al.
LANCET ONCOLOGY (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Meenakshi Anurag et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2020)
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Man Yee Keung et al.
JOURNAL OF CLINICAL MEDICINE (2020)
De-escalated therapy for HR+/HER2+breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri et al.
ANNALS OF ONCOLOGY (2019)
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
Elena Lopez-Knowles et al.
BRITISH JOURNAL OF CANCER (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mutant p53 gain of function induces HER2 over-expression in cancer cells
A. A. Roman-Rosales et al.
BMC CANCER (2018)
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
Juan Miguel Cejalvo et al.
CANCER TREATMENT REVIEWS (2018)
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers
Meenakshi Anurag et al.
CLINICAL CANCER RESEARCH (2018)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Lesley-Ann Martin et al.
NATURE COMMUNICATIONS (2017)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Anita K. Dunbier et al.
CLINICAL CANCER RESEARCH (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
p53 mutation, deprivation and poor prognosis in primary breast cancer
L. Baker et al.
BRITISH JOURNAL OF CANCER (2010)
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Isabel F. Pinhel et al.
BREAST CANCER RESEARCH (2010)
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Aleix Prat et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
M Dowsett et al.
CLINICAL CANCER RESEARCH (2006)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data
S Monti et al.
MACHINE LEARNING (2003)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
